Literature DB >> 12936990

Optimal sampling schedule design for populations of patients.

Vincent H Tam1, Sandra L Preston, G L Drusano.   

Abstract

Generation of pharmacodynamic relationships in the clinical arena requires estimation of pharmacokinetic parameter values for individual patients. When the target population is severely ill, the ability to obtain traditional intensive blood sampling schedules is curtailed. Population modeling guided by optimal sampling theory has provided robust estimates of individual patient pharmacokinetic parameter values. Because of the wide range of parameter values seen in this circumstance, it is important to know how the range of parameter values in the population affects the timing of the optimal samples. We describe a new, simple technique to obtain optimal samples for a population of patients. This technique uses the nonparametric distribution associated with a nonparametric adaptive grid population pharmacokinetic analysis. We used the distribution from an analysis of 58 patients receiving levofloxacin for nosocomial pneumonia at a dose of 750 mg. The collection of parameter vectors and their associated probabilities were entered into a D-optimal design evaluation by using ADAPT II. The sampling times, weighted for their probabilities, were displayed in a frequency histogram (an expression of how system information varies with time for the population). Such an explicit expression of the time distribution of information allows rational sampling design that is robust not only for the population mean vector, as in traditional D-optimal design theory, but also for large portions of the total population. For levofloxacin, one reasonable six-sample design would be 1.5, 2, 2.25, 4, 4.75, and 24 h after starting a 90-min infusion. Such sampling designs allow informative population pharmacokinetic analysis with precise and unbiased estimates after the maximal a posteriori probability Bayesian step. This allows the highest probability of delineating a pharmacodynamic relationship.

Entities:  

Mesh:

Year:  2003        PMID: 12936990      PMCID: PMC182630          DOI: 10.1128/AAC.47.9.2888-2891.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Optimal sampling theory and population modelling: application to determination of the influence of the microgravity environment on drug distribution and elimination.

Authors:  G L Drusano
Journal:  J Clin Pharmacol       Date:  1991-10       Impact factor: 3.126

2.  Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics.

Authors:  M Tod; J M Rocchisani
Journal:  J Pharmacokinet Biopharm       Date:  1997-08

3.  Rapid stereospecific high-performance liquid chromatographic determination of levofloxacin in human plasma and urine.

Authors:  F A Wong; S J Juzwin; S C Flor
Journal:  J Pharm Biomed Anal       Date:  1997-03       Impact factor: 3.935

4.  Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.

Authors:  S L Preston; G L Drusano; A L Berman; C L Fowler; A T Chow; B Dornseif; V Reichl; J Natarajan; F A Wong; M Corrado
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 5.  Estimating population kinetics.

Authors:  S L Beal; L B Sheiner
Journal:  Crit Rev Biomed Eng       Date:  1982

6.  Implementation of OSPOP, an algorithm for the estimation of optimal sampling times in pharmacokinetics by the ED, EID and API criteria.

Authors:  M Tod; J M Rocchisani
Journal:  Comput Methods Programs Biomed       Date:  1996-06       Impact factor: 5.428

7.  Population pharmacokinetics of procainamide from routine clinical data.

Authors:  T H Grasela; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

8.  An evaluation of optimal sampling strategy and adaptive study design.

Authors:  G L Drusano; A Forrest; M J Snyder; M D Reed; J L Blumer
Journal:  Clin Pharmacol Ther       Date:  1988-08       Impact factor: 6.875

9.  Optimal sampling theory: effect of error in a nominal parameter value on bias and precision of parameter estimation.

Authors:  G L Drusano; A Forrest; G Yuen; K Plaisance; J Leslie
Journal:  J Clin Pharmacol       Date:  1994-10       Impact factor: 3.126

10.  A prospective evaluation of optimal sampling theory in the determination of the steady-state pharmacokinetics of piperacillin in febrile neutropenic cancer patients.

Authors:  G L Drusano; A Forrest; K I Plaisance; J C Wade
Journal:  Clin Pharmacol Ther       Date:  1989-06       Impact factor: 6.875

View more
  16 in total

1.  Is One Sample Enough? β-Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model.

Authors:  Ana Motos; Joseph L Kuti; Gianluigi Li Bassi; Antoni Torres; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

Review 2.  The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.

Authors:  T Tängdén; V Ramos Martín; T W Felton; E I Nielsen; S Marchand; R J Brüggemann; J B Bulitta; M Bassetti; U Theuretzbacher; B T Tsuji; D W Wareham; L E Friberg; J J De Waele; V H Tam; Jason A Roberts
Journal:  Intensive Care Med       Date:  2017-04-13       Impact factor: 17.440

3.  Pharmacokinetic/Pharmacodynamic antimicrobial individualization and optimization strategies.

Authors:  Tze-Peng Lim; Kevin W Garey; Vincent H Tam
Journal:  Curr Infect Dis Rep       Date:  2008-03       Impact factor: 3.725

4.  Population pharmacokinetics of voriconazole in adults.

Authors:  William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

5.  Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation.

Authors:  Christopher Vinnard; Shruthi Ravimohan; Neo Tamuhla; Vijay Ivaturi; Jotam Pasipanodya; Shashikant Srivastava; Chawangwa Modongo; Nicola M Zetola; Drew Weissman; Tawanda Gumbo; Gregory P Bisson
Journal:  Br J Clin Pharmacol       Date:  2016-12-09       Impact factor: 4.335

6.  Optimizing ethambutol dosing among HIV/tuberculosis co-infected patients: a population pharmacokinetic modelling and simulation study.

Authors:  Krina Mehta; Shruthi Ravimohan; Jotam G Pasipanodya; Shashikant Srivastava; Chawangwa Modongo; Nicola M Zetola; Drew Weissman; Vijay Ivaturi; Tawanda Gumbo; Gregory P Bisson; Christopher Vinnard
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

7.  Population pharmacokinetics of micafungin in neonates and young infants.

Authors:  William W Hope; P Brian Smith; Antonio Arrieta; Donald N Buell; Michael Roy; Atsunori Kaibara; Thomas J Walsh; Michael Cohen-Wolkowiez; Daniel K Benjamin
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

Review 8.  Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations.

Authors:  Cornelia B Landersdorfer; Jürgen B Bulitta; Martina Kinzig; Ulrike Holzgrabe; Fritz Sörgel
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model.

Authors:  Beatriz E Ferro; Shashikant Srivastava; Devyani Deshpande; Carleton M Sherman; Jotam G Pasipanodya; Dick van Soolingen; Johan W Mouton; Jakko van Ingen; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

10.  Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections.

Authors:  T W Felton; W W Hope; B M Lomaestro; J M Butterfield; A L Kwa; G L Drusano; T P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.